Table 2.
Treatment strategies harnessing FcRn function
| Treatment | Disease/Indication | Treatment strategy | Reference or ClinicalTrials.gov identifier |
|---|---|---|---|
| Efgartigimod (ARGX-113) |
MG CIDP |
Antagonism of FcRn (IgG1-derived Fc fragment with high affinity for FcRn) | [2, 78] |
| Nipocalimab | MG | Antagonism of FcRN (Abdeg, aglycosylated IgG1 mAb against FcRn) | NCT04951622 (recruiting) |
| Rozanolixizumab |
MG CIDP |
Antagonism of FcRn (Abdeg, humanized mAb against FcRn) | [80, 96] |
| Orilanolimab (SYNT001) | MG | Antagonism of FcRn (Abdeg, IgG4 mAb against FcRn) | [30] |
| CSL730/M230 | Unknown | Antagonism of FcRn (Abdeg, IgG1 Fc multimer against FcRn) |
NCT03375606 (terminated) NCT04446000 (ongoing) |
| Batoclimab (RVT-1401) |
MG CIDP NMSOD |
Antagonism of FcRn (Abdeg, mAb against FcRN) |
[111] NCT04346888 (completed) |
| MOG-Seldeg | NMSOD | Selective degradation of pathogenic Abs (Seldeg, recombinant MOG protein linked to a human IgG1-derived Fc fragment with high affinity for FcRn) | [81, 82] |
| Ravulizumab |
MG NMSOD |
Increased half-life of anti-C5-mAb (mAb with high affinity for FcRn, created by modifying Eculizumab) |
[87] NCT03920293 (MG, active, not recruiting) NCT04201262 (NMSOD, active, not recruiting) |
| Satrulizumab | NMSOD | IgG2 mAb against IL-6, binds FcRn for recycling and prolonged half-life |
[88] NCT02028884 (active, not recruiting) |
Ab antibody, abdeg antibody-based FcRn inhibitor, CIDP chronic inflammatory demyelinating polyneuropathy, MG myasthenia gravis, NMSOD neuromyelitis optica spectrum disorders, seldeg selective degradation